| [1] |
Hao G, Wang X, Chen Z, et al. Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012-2015[J]. Eur J Heart Fail, 2019, 21(11): 1329-1337.
|
| [2] |
Metra M, Lucioli P. Corrigendum to 'Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012-2015' [Eur J Heart Fail 2019; 21: 1329-1337][J]. Eur J Heart Fail, 2020, 22(4): 759.
|
| [3] |
Chioncel O, Parissis J, Mebazaa A, et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail, 2020, 22(8):1315-1341.
|
| [4] |
Al Danaf J, Butler J, Yehya A. Updates on device-based therapies for patients with heart failure[J]. Curr Heart Fail Rep, 2018, 15(2):53-60.
|
| [5] |
Jones EC, Devereux RB, Roman MJ, et al. Prevalence and correlates of mitral regurgitation in a population-based sample (the Strong Heart Study) [J]. Am J Cardiol, 2001, 87(3): 298-304.
|
| [6] |
Feldman T, Kar S, Elmariah S, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II[J]. J Am Coll Cardiol, 2015, 66(25):2844-2854.
|
| [7] |
Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe[J]. J Am Coll Cardiol, 2013, 62(12):1052-1061.
|
| [8] |
Iung B, Armoiry X, Vahanian A, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years[J]. Eur J Heart Fail, 2019, 21(12):1619-1627.
|
| [9] |
Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation[J]. N Engl J Med, 2018, 379(24):2297-2306.
|
| [10] |
Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure[J]. N Engl J Med, 2018, 379(24):2307-2318.
|
| [11] |
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2021, 143(5): e35-e71.
|
| [12] |
Orban M, Rottbauer W, Williams M, et al. Transcatheter edge-to-edge repair for secondary mitral regurgitation with third-generation devices in heart failure patients - results from the Global EXPAND Post-Market study[J]. Eur J Heart Fail, 2023, 25(3):411-421.
|
| [13] |
Popolo Rubbio A, Testa L, Grasso C, et al. Transcatheter edge-to-edge mitral valve repair in atrial functional mitral regurgitation: insights from the multi-center MITRA-TUNE registry[J]. Int J Cardiol, 2022, 349:39-45.
|
| [14] |
Sodhi N, Asch FM, Ruf T, et al. Clinical outcomes with transcatheter edge-to-edge repair in atrial functional MR from the EXPAND study[J]. JACC Cardiovasc Interv, 2022, 15(17):1723-1730.
|
| [15] |
Witte KK, Lipiecki J, Siminiak T, et al. The REDUCE FMR trial: a randomized sham-controlled study of percutaneous mitral annuloplasty in functional mitral regurgitation[J]. JACC Heart Fail, 2019, 7(11): 945-955.
|
| [16] |
Muller D, Sorajja P, Duncan A, et al. 2-Year outcomes of transcatheter mitral valve replacement in patients with severe symptomatic mitral regurgitation[J]. J Am Coll Cardiol, 2021, 78(19):1847-1859.
|
| [17] |
Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)[J]. Am J Cardiol, 1999, 83(6):897-902.
|
| [18] |
Vargas Abello LM, Klein AL, Marwick TH, et al. Understanding right ventricular dysfunction and functional tricuspid regurgitation accompanying mitral valve disease[J]. J Thorac Cardiovasc Surg, 2013, 145(5):1234-1241.e5.
|
| [19] |
Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation[J]. N Engl J Med, 2023, 388(20):1833-1842.
|
| [20] |
陈丹丹, 潘文志, 陈莎莎, 等. 结构性心脏病年度报告2022 [J/OL]. 中华心脏与心律电子杂志, 2023, 11(3): 129-140.
|
| [21] |
Mao Y, Li L, Liu Y, et al. Safety, efficacy, and clinical outcomes of transcatheter tricuspid valve replacement: one-year follow-up[J]. Front Cardiovasc Med, 2022, 9:1019813.
|
| [22] |
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients[J]. N Engl J Med, 2019, 380(18):1695-1705.
|
| [23] |
Forrest JK, Deeb GM, Yakubov SJ, et al. 2-Year outcomes after transcatheter versus surgical aortic valve replacement in low-risk patients[J]. J Am Coll Cardiol, 2022, 79(9):882-896.
|
| [24] |
中国医师协会心血管内科医师分会结构性心脏病专业委员会. 中国经导管主动脉瓣置换术临床路径专家共识(2021版)[J]. 中国循环杂志, 2022, 37(1):12-23.
|
| [25] |
Spitzer E, Van Mieghem NM, Pibarot P, et al. Rationale and design of the transcatheter aortic valve replacement to unload the left ventricle in patients with advanced heart failure (TAVR UNLOAD) trial[J]. Am Heart J, 2016, 182:80-88.
|
| [26] |
Gustafsson F, Rogers JG. Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes[J]. Eur J Heart Fail, 2017, 19(5):595-602.
|
| [27] |
Mehra MR, Goldstein DJ, Uriel N, et al. Two-year outcomes with a magnetically levitated cardiac pump in heart failure[J]. N Engl J Med, 2018, 378(15):1386-1395.
|
| [28] |
Mehra MR, Uriel N, Naka Y, et al. A fully magnetically levitated left ventricular assist device - final report[J]. N Engl J Med, 2019, 380(17):1618-1627.
|
| [29] |
Hendriks T, Schurer R, Al Ali L, et al. Left ventricular restoration devices post myocardial infarction[J]. Heart Fail Rev, 2018, 23(6):871-883.
|
| [30] |
Yang YJ, Huo Y, Xu YW, et al. Percutaneous ventricular restoration therapy using the parachute device in Chinese patients with ischemic heart failure: three-month primary end-point results of PARACHUTE China study[J]. Chin Med J (Engl), 2016, 129(17):2058-2062.
|
| [31] |
Thomas M, Nienaber CA, Ince H, et al. Percutaneous ventricular restoration (PVR) therapy using the Parachute device in 100 subjects with ischaemic dilated heart failure: one-year primary endpoint results of PARACHUTE III, a European trial[J]. Euro Intervention, 2015, 11(6): 710-717.
|
| [32] |
Zhu Z, Zhu J, Yu J, et al. Percutaneous ventricular restoration prevents left ventricular remodeling post myocardial infarction: one-year evaluation of the Heartech first-in-man study[J]. J Card Fail, 2022, 28(4):604-613.
|
| [33] |
Klein P, Anker SD, Wechsler A, et al. Less invasive ventricular reconstruction for ischaemic heart failure[J]. Eur J Heart Fail, 2019, 21(12):1638-1650.
|
| [34] |
Mann DL, Lee RJ, Coats AJ, et al. One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure[J]. Eur J Heart Fail, 2016, 18(3):314-325.
|
| [35] |
Wang B, Lee RJ, Tao L. First-in-human transcatheter endocardial alginate-hydrogel implantation for the treatment of heart failure[J]. Eur Heart J, 2023, 44(4):326.
|
| [36] |
Fudim M, Abraham WT, von Bardeleben RS, et al. Device therapy in chronic heart failure: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2021, 78(9):931-956.
|
| [37] |
Griffin JM, Borlaug BA, Komtebedde J, et al. Impact of interatrial shunts on invasive hemodynamics and exercise tolerance in patients with heart failure[J]. J Am Heart Assoc, 2020, 9(17):e016760.
|
| [38] |
Shah SJ, Borlaug BA, Chung ES, et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial[J]. Lancet, 2022, 399(10330):1130-1140.
|
| [39] |
Shang X, Liu M, Zhong Y, et al. Clinical study on the treatment of chronic heart failure with a novel D-shant atrium shunt device[J]. ESC Heart Fail, 2022, 9(3):1713-1720.
|
| [40] |
Naqvi SY, Jawaid A, Goldenberg I, et al. Non-response to cardiac resynchronization therapy[J]. Curr Heart Fail Rep, 2018, 15(5):315-321.
|
| [41] |
Kato H, Yanagisawa S, Sakurai T, et al. Efficacy of His bundle pacing on LV relaxation and clinical improvement in HF and LBBB[J]. JACC Clin Electrophysiol, 2022, 8(1):59-69.
|
| [42] |
Huang W, Wu S, Vijayaraman P, et al. Cardiac resynchronization therapy in patients with nonischemic cardiomyopathy using left bundle branch pacing[J]. JACC Clin Electrophysiol, 2020, 6(7): 849-858.
|
| [43] |
Wu S, Su L, Vijayaraman P, et al. Left bundle branch pacing for cardiac resynchronization therapy: nonrandomized on-treatment comparison with His bundle pacing and biventricular pacing[J]. Can J Cardiol, 2021, 37(2):319-328.
|
| [44] |
Vijayaraman P, Ponnusamy S, Cano Ó, et al. Left bundle branch area pacing for cardiac resynchronization therapy: results from the international LBBAP collaborative study group[J]. JACC Clin Electrophysiol, 2021, 7(2):135-147.
|
| [45] |
汤宝鹏, 董震宇. 心肌收缩力调节器的最佳适应证人群选择 [J/OL]. 中华心脏与心律电子杂志, 2022, 10(3): 129-132.
|
| [46] |
Kuschyk J, Falk P, Demming T, et al. Long-term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system[J]. Eur J Heart Fail, 2021, 23(7):1160-1169.
|
| [47] |
Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail, 2019, 21(10):1169-1186.
|
| [48] |
Abraham WT, Zile MR, Weaver FA, et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction[J]. JACC Heart Fail, 2015, 3(6):487-496.
|
| [49] |
Miyagi C, Miyamoto T, Karimov JH, et al. Device-based treatment options for heart failure with preserved ejection fraction[J]. Heart Fail Rev, 2021, 26(4):749-762.
|
| [50] |
Zile MR, Lindenfeld J, Weaver FA, et al. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction[J]. J Am Coll Cardiol, 2020, 76(1):1-13.
|
| [51] |
Coats A, Abraham WT, Zile MR, et al. Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials[J]. Eur J Heart Fail, 2022, 24(9):1665-1673.
|
| [52] |
Gold MR, Van Veldhuisen DJ, Hauptman PJ, et al. Vagus nerve stimulation for the treatment of heart failure: The INOVATE-HF trial[J]. J Am Coll Cardiol, 2016, 68(2):149-158.
|
| [53] |
Konstam MA, Udelson JE, Butler J, et al. Impact of autonomic regulation therapy in patients with heart failure: ANTHEM-HFrEF pivotal study design[J]. Circ Heart Fail, 2019, 12(11):e005879.
|
| [54] |
Fudim M, Zirakashvili T, Shaburishvili N, et al. Transvenous right greater splanchnic nerve ablation in heart failure and preserved ejection fraction: first-in-human study[J]. JACC Heart Fail, 2022, 10(10):744-752.
|
| [55] |
Fudim M, Fail PS, Litwin SE, et al. Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE-HF trial roll-in cohort[J]. Eur J Heart Fail, 2022, 24(8):1410-1414.
|